Zai Lab Limited (ZLAB) Stock Price & How to Invest

Zai Lab was built on a specific arbitrage: find drugs that already work, license the Greater China rights before or during late-stage development, run the local trials and regulatory process, and sell them through a domestic commercial organization that Western partners do not want to build. That produced a portfolio of marketed products including ZEJULA (niraparib, a PARP inhibitor for ovarian cancer), the VYVGART franchise (efgartigimod, partnered with argenx, for generalized myasthenia gravis), XACDURO (sulbactam-durlobactam for Acinetobacter infections) and NUZYRA (omadacycline), with newer approvals for AUGTYRO, TIVDAK and KarXT rolling into launch through 2026. Total revenue was about $460 million in 2025 and roughly $450 million over the trailing twelve months, and management has described the China commercial business as profitable on its own before corporate R&D.

The second half of the story is the part the market is actually arguing about. Zai Lab has spent years converting itself from a licensing vehicle into a discovery company that owns worldwide rights, and the flagship is zocilurtatug pelitecan (zoci, formerly ZL-1310), an internally discovered DLL3-targeting antibody drug conjugate aimed at small cell lung cancer and neuroendocrine carcinomas. Early Phase 1 data showed roughly a 68% overall response rate with a 94% disease control rate, a 62.5% confirmed intracranial response rate in patients with brain metastases presented at AACR 2026, and the FDA granted orphan drug designation for neuroendocrine carcinomas. Against that, the licensed side has been taking hits: generic olaparib entering volume-based procurement pushed ZEJULA from about $49.5 million in Q1 2025 to $30.0 million in Q1 2026, VYVGART absorbed price cuts tied to national reimbursement list renewal, and the Amgen-partnered bemarituzumab program deteriorated after the FORTITUDE-101 final analysis showed an attenuated survival benefit. Q2 2026 revenue of about $106.3 million beat consensus and rose roughly 11% sequentially on product sales, and the shares rose about 14% on the day, but the stock is still down more than 40% over the past year.

Zai Lab's revenue is concentrated in mainland China and is therefore exposed to administered pricing rather than market pricing: national reimbursement drug list renewals cut prices as a condition of volume, and volume-based procurement of generics can collapse a branded franchise quickly, which is what happened to ZEJULA when generic olaparib entered. The company has not reached consolidated profitability, has lost roughly $188 million over the trailing twelve months, and previously pushed out its own profitability timeline. The pipeline carries binary clinical risk, and the bemarituzumab experience is the cautionary case: an interim survival benefit attenuated at final analysis in FORTITUDE-101, and the related FORTITUDE-102 study was stopped. Multiple plaintiffs' law firms have publicly announced investigations tied to those disclosures and to earlier Holding Foreign Companies Accountable Act developments, which is a live overhang even where no certified class action has been reported. The dual Nasdaq and Hong Kong listing adds geopolitical, audit-oversight and currency exposure that a purely US-listed biotech of similar size does not carry, and the ADSs have traded between roughly $15.96 and $39.32 over the past year.

12 analysts publish price targets on ZLAB, averaging $33.30 against a $20.88 price as of August 2026, or +59.5%. The published targets run from $21.60 to $52.00, a wide spread, and the ratings split 11 buy, 1 hold, 0 sell. Over the last six months there have been 0 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ZLAB forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Zai Lab Limited. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Zoci as the first globally owned asset. Zocilurtatug pelitecan is a DLL3-targeting antibody drug conjugate that Zai Lab discovered internally and controls worldwide, which is a structural break from the in-licensing model where economics stop at the Chinese border. The most optimistic published target, $52.00, assumes this works close to its best case.

The case against. Zai Lab's revenue is concentrated in mainland China and is therefore exposed to administered pricing rather than market pricing: national reimbursement drug list renewals cut prices as a condition of volume, and volume-based procurement of generics can collapse a branded franchise quickly, which is what happened to ZEJULA when generic olaparib entered. The most pessimistic target, $21.60, is roughly what ZLAB is worth if this bites instead.

Read the full bull and bear case on ZLAB, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Zai Lab Limited's investor relations page or your broker.

• Revenue (TTM): ~$450 million, up ~5% year over year
• Q2 2026 revenue: ~$106.3 million, down ~3% year over year but up ~11% sequentially on product sales
• Net loss: ~$50.8 million in Q2 2026, ~$188 million over the trailing twelve months
• Cash and investments: ~$717.5 million as of June 30, 2026
• Market cap: ~$2.35 billion at ~$20.88 an ADS, roughly ~$1.6 billion enterprise value
• Enterprise value to revenue: ~3.6x trailing revenue, versus ~5.2x on market cap

There is no earnings multiple to quote because Zai Lab does not earn anything yet, so the stock is valued on revenue, cash and pipeline probability instead. Backing out roughly $717 million of cash leaves about $1.6 billion of enterprise value against $450 million of trailing revenue, which is a low multiple for a specialty pharma commercial base and implies the market assigns close to nothing for the wholly owned oncology pipeline. Bulls point at that gap, bears point at a revenue line that shrank year over year in both Q1 and Q2 2026 while operating expenses stayed above $130 million a quarter.

Other names that sit close to ZLAB: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ZLAB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ZLAB sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ZLAB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Zai Lab is a real commercial business with four-plus marketed drugs in China funding an unproven global oncology pipeline, and the stock prices that split identity at a discount to both halves.

Whether ZLAB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ZLAB a buy or a sell?, and where the stock could go from here in the ZLAB stock forecast.

For income investors, whether ZLAB pays a dividend and how the payout looks is covered in does ZLAB pay a dividend? And to weigh ZLAB against a peer, read the full side-by-side comparisons: ZLAB vs LEGN and ZLAB vs ADC.